AtomVie and Radiopharm's Strategic Partnership
AtomVie Global Radiopharma, a renowned contract development and manufacturing organization (CDMO), has formed a strategic alliance with Radiopharm Ventures, a joint venture that boasts a collaboration between Radiopharm Theranostics and a well-regarded cancer research institution. This significant partnership is aimed at the development and manufacturing of 177Lu-BetaBart, a targeted radioantibody designed to potentially address multiple solid tumors effectively.
Understanding the Importance of B7-H3 in Cancer Treatment
B7-H3 is an immune checkpoint molecule that is prominently expressed in various tumor types, making it an appealing target for innovative cancer therapies. Studies suggest that the deregulated expression of B7-H3 correlates with the aggressiveness of tumors and unfavourable patient outcomes. The 177Lu-BetaBart, the first of its kind targeting the 4Ig subtype of B7-H3, has been engineered to minimize off-target toxicity, significantly enhancing its safety profile for clinical use.
Clinical Trials and Future Expectations
As the partnership gears up for future development, a Phase I/II clinical trial of 177Lu-BetaBart is anticipated to commence around mid-2025 in the United States. This trial represents an exciting leap forward in exploring novel therapeutic options for patients with several challenging tumor types. The potential benefits of the therapy could open new doors for patients who have previously exhausted conventional treatments.
Combining Expertise for Better Outcomes
The collaboration leverages both parties' strengths: AtomVie brings to the table its extensive experience in the formulation and global distribution of radiopharmaceuticals, while Radiopharm Ventures contributes proprietary technologies aimed at advancing cancer care. The integration of AtomVie’s leading-edge manufacturing capabilities with RAD’s innovative product pipeline signifies an unprecedented stride towards enhancing the landscape of cancer therapy.
Advancing Towards Commercialization
With AtomVie’s state-of-the-art facility spanning over 72,300 square feet, which is set to open soon, the organization is well-poised to support a burgeoning pipeline of radiotherapeutics. This facility will also provide the capability to oversee critical processes ranging from clinical trials to eventual market launch, ensuring that the path from development to patient care is smooth and effective.
Statements from Company Leaders
Expressing his enthusiasm for the collaboration, Riccardo Canevari, CEO of Radiopharm Theranostics, emphasized the importance of teaming up with a reliable partner. He stated, "Our collaboration with AtomVie marks a pivotal moment in our quest to deliver groundbreaking radiopharmaceutical therapies. Their impressive manufacturing capabilities give us confidence as we transition toward commercialization."
Bruno Paquin, CEO of AtomVie, echoed these sentiments, detailing how their strengths can combine to transform patient care. He affirmed, "We are excited to work alongside RAD on such an important initiative. Our extensive knowledge in the radiopharmaceutical space positions us to assist RAD in advancing promising therapies towards clinical use."
About AtomVie Global Radiopharma Inc.
As a global leader in GMP manufacturing and the distribution of radiopharmaceuticals, AtomVie offers a unique blend of scientific, technical, and regulatory expertise. Their comprehensive approach encompasses everything from initial clinical studies to commercial distribution, ensuring clients receive robust support throughout their research and development phases. AtomVie’s services extend to international markets, aiding trials in over 25 countries worldwide.
About Radiopharm Theranostics and Radiopharm Ventures
Radiopharm Therapostics focuses on developing innovative oncology-focused radiopharmaceuticals for significant unmet medical needs. Their diverse pipeline showcases a range of distinct technologies—including peptides and monoclonal antibodies—developed in collaboration with leading global institutions. Together with MD Anderson Cancer Center through Radiopharm Ventures, they aim to harness cutting-edge research for real-world application.
Frequently Asked Questions
What is 177Lu-BetaBart?
177Lu-BetaBart is a targeted radioantibody designed to inhibit tumor growth, utilizing the 4Ig subtype of the B7-H3 molecule, which is commonly expressed in various cancers.
When is the clinical trial for 177Lu-BetaBart expected to start?
The Phase I/II clinical trial for 177Lu-BetaBart is expected to begin around mid-2025 in the United States.
What companies are involved in this partnership?
The partnership is primarily between AtomVie Global Radiopharma and Radiopharm Ventures, a venture involving Radiopharm Theranostics and MD Anderson Cancer Center.
Where is AtomVie's manufacturing facility located?
AtomVie is set to open a new state-of-the-art manufacturing facility that spans 72,300 square feet, which will enhance their capabilities in producing radiopharmaceuticals.
What is the goal of this collaboration?
The main goal is to advance the development of innovative radiopharmaceutical therapies to improve treatment options for patients with solid tumors and other cancers.
